1
Andrew A Young, Bronislava Gedulin, Nigel Robert Arnold Beeley, Kathryn S Prickett: Methods for regulating gastrointestinal motility. Amylin Pharmaceuticals, Arnold & Porter, February 22, 2005: US06858576 (53 worldwide citation)

Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist. Methods for treating conditions associated with elevated, inappropriate, or undesired po ...


2
Andrew A Young, Bronislava Gedulin: Methods for glucagon suppression. Amylin Pharmaceuticals, Arnold & Porter, March 29, 2005: US06872700 (49 worldwide citation)

Methods for use of an exendin, an exendin agonist, or a modified exendin or exendin agonist having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, for lowering glucagon levels and/or suppressing glucagon secretion in a subject are provide. These methods ...


3
Kathryn S Prickett, Andrew A Young: Modified exendins and exendin agonists. Amylin Pharmaceuticals, Arnold & Porter, August 2, 2005: US06924264 (49 worldwide citation)

Novel modified exendins and exendin agonist analogs having an exendin or exendin agonist analog linked to one or more polyethylene glycol polymers, for example, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonist analog ...


4
Orville G Kolterman, Andrew A Young: Exendin agonist formulations and methods of administration thereof. Amylin Pharmaceuticals, Arnold & Porter, June 7, 2005: US06902744 (45 worldwide citation)

Novel exendin and exendin agonist compound formulations and dosages and methods of administration thereof are provided. These compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhi ...


5
Andrew A Young, Will Vine, Nigel R A Beeley, Kathryn Prickett: Inotropic and diuretic effects of exendin and GLP-1. Amylin Pharmaceuticals, Arnold & Porter, March 9, 2004: US06703359 (42 worldwide citation)

Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treati ...


6
Andrew A Young, Bronislava Gedulin: Methods for glucagon suppression using modified exendins. Amylin Pharmaceuticals, December 26, 2006: US07153825 (36 worldwide citation)

We claim a method of lowering plasma glucagon in a subject in need thereof comprising administering to the subject a composition comprising a modified exendin or modified exendin analog, wherein said modification comprises one or more molecule linked to an exendin or the exendin analog wherein said ...


7
Orville G Kolterman, Andrew A Young, Timothy J Rink, Kathleen Ann Keiting Brown: Methods for regulating gastrointestinal motility. Amylin Pharmaceuticals, Lyon & Lyon, September 5, 2000: US06114304 (33 worldwide citation)

Methods for treating conditions associated with elevated, inappropriate or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an amylin agonist alone or in conjunction with other anti-gastric emptying agents. Methods for reducing gastri ...


8
Timothy J Rink, Andrew A Young, Nigel Robert Arnold Beeley, Kathryn S Prickett: Appetite regulating compositions. Lyon & Lyon, April 14, 1998: US05739106 (26 worldwide citation)

Compositions and methods for reducing food intake, suppressing appetite and controlling body weight are provided. Such compositions may include an amylin agonist and a CCK agonist or a hybrid peptide.


9
Andrew A Young, Sunil Bhavsar, Bronislava Gedulin: Exendins and exendin agonists for weight reduction and obesity. Amylin Pharmaceuticals, June 22, 2010: US07741269 (21 worldwide citation)

Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are usefu ...


10
Andrew A Young, Will Vine, Nigel R A Beeley, Kathryn Prickett: Inotropic and diuretic effects of GLP-1 and GLP-1 agonists. Amylin Pharmaceuticals, October 28, 2008: US07442680 (20 worldwide citation)

Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treati ...